A Phase Ib Study Combining Irinotecan With AZD1775 a Selective Wee 1 Inhibitor in RAS (KRAS or NRAS) or BRAF Mutated Metastatic Colorectal Cancer Patients Who Have Progressed on First Line Therapy
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.